Back to Results
First PageMeta Content
Peptide hormones / Pharmacology / Drug discovery / Porphyrias / Afamelanotide / Pharmaceutical industry / Erythropoietic protoporphyria / Actinic keratosis / Alpha-Melanocyte-stimulating hormone / Medicine / Health / Pharmaceutical sciences


Document Date: 2012-04-19 14:38:07

Open Document

File Size: 98,99 KB

Share Result on Facebook

City

Rimini / Melbourne / /

Company

Business Operations Europe Clinuvel Pharmaceuticals Limited T / Clinuvel Pharmaceuticals Limited / Communications Clinuvel Pharmaceuticals Limited T / /

Continent

Europe / /

Country

Switzerland / Italy / United States / Australia / /

/

Event

FDA Phase / /

IndustryTerm

pharmaceutical development / treatment of the proposed disease / cancer treatment / biopharmaceutical / pharmaceutical products / pharmaceutical environment / /

MedicalCondition

anaphylactic reaction / orphan indication porphyria / rare metabolic disorder / inherited disorders / Porphyrias / Recipients (OTRs) Skin cancer / porphyria / orphan diseases / Actinic Keratosis / Squamous Cell Carcinoma / cancer / disease / severe phototoxicity / pain / enzymatic deficiency / rare genetic disease / sun/UV Phototoxicity / erythropoietic porphyrias / erythropoietic protoporphyria / disorders / rare and severe disease / /

MedicalTreatment

alternative therapy / radiation / Photodynamic Therapy / Organ Transplant / /

Organization

Australia Italian Medicines Agency / FDA’s office of Orphan Products Development / Congress / European Medicines Agency / Scientific Committee / FDA / Technical and Scientific Committee / /

Person

Hank Agersborg / Philippe Wolgen / /

/

Position

Chief Scientific Officer / CEO / investorrelations@clinuvel.com Europe Daniela Schaefer Head / Australia Lachlan Hay Head of Global Network / /

Product

Australia / Afamelanotide / /

RadioStation

XETRA / /

Technology

radiation / drug development / /

URL

http /

SocialTag